These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 8146847)

  • 1. [A one-year prospective and intensive pharmacovigilance of antilipemic drugs in an hospital consultation for prevention of risk factors].
    Jacquet A; Colomes M; Ferrieres J; Denat M; Douste-Blazy P; Monstastruc JL
    Therapie; 1993; 48(5):509-12. PubMed ID: 8146847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacovigilance of hypolipidemic drugs (fibrates and probucol), from databanks of the French System of Pharmacovigilance].
    Therapie; 1991; 46(5):345-6. PubMed ID: 1754975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyslipidemia and atherosclerosis. A forecast of pharmaceutical approaches.
    Gotto AM
    Circulation; 1993 Apr; 87(4 Suppl):III54-9. PubMed ID: 8462181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
    Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
    J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of ten years of pharmacovigilance of antihypertensive drugs in the Toulouse University Regional Hospital Center (1981-1990)].
    Jacquet A; Sorbette F; Montastruc JL
    Therapie; 1993; 48(2):141-4. PubMed ID: 8351683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of atherosclerosis in diabetes: emphasis on treatment for the abnormal lipoprotein metabolism of diabetes.
    Kim DK; Escalante DA; Garber AJ
    Clin Ther; 1993; 15(5):766-78; discussion 765. PubMed ID: 8269443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is exposure to HMG-CoA reductase inhibitors (statins), fibrates, or other lipid-lowering drugs associated with reduced risk of bone fracture in older patients?
    Douglas LO
    J Fam Pract; 2000 Sep; 49(9):849-50. PubMed ID: 11032211
    [No Abstract]   [Full Text] [Related]  

  • 10. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antilipemic therapy and rhabdomyolysis].
    Paragh G; Balogh Z; Romics L
    Orv Hetil; 2003 Mar; 144(11):515-20. PubMed ID: 12731338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacovigilance of self-medication].
    Montastruc JL; Bagheri H; Geraud T; Lapeyre-Mestre M
    Therapie; 1997; 52(2):105-10. PubMed ID: 9231503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis.
    Shah PK
    Rev Cardiovasc Med; 2003; 4(3):136-41. PubMed ID: 12949442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
    J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care].
    Jancsó Z; Varga Z; Simay A; Ilyés I
    Orv Hetil; 2005 Dec; 146(52):2629-33. PubMed ID: 16468604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study.
    Dufouil C; Richard F; Fiévet N; Dartigues JF; Ritchie K; Tzourio C; Amouyel P; Alpérovitch A
    Neurology; 2005 May; 64(9):1531-8. PubMed ID: 15883313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro.
    Kreuzer J; Watson L; Herdegen T; Loebe M; Wende P; Kübler K
    Eur J Med Res; 1999 Apr; 4(4):135-43. PubMed ID: 10205288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thailand diabetes registry project: current status of dyslipidemia in Thai diabetic patients.
    Pratipanawatr T; Rawdaree P; Chetthakul T; Bunnag P; Ngarmukos C; Benjasuratwong Y; Leelawatana R; Kosachunhanun N; Plengvidhya N; Deerochanawong C; Suwanwalaikorn S; Krittiyawong S; Mongkolsomlit S; Komoltri C
    J Med Assoc Thai; 2006 Aug; 89 Suppl 1():S60-5. PubMed ID: 17715835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.